Agresta L, et al. - Authors contemplated the efficacy of Pazopanib for the treatment of desmoid tumors/aggressive fibromatosis (DT/AF) in adolescent and young adult (AYA) patients aged 3–21 years. As per the data, pazopanib exhibited best responses by RECIST of partial response (PR) in 2 of 7 and stable disease (SD) in 6 of 7 tumors. Subjects reported pain relief and improvement in function within 1 month. It was observed that the mesenteric DT/AF also illustrated PR. Findings displayed that the maximum volumetric decrease by T2-weighted magnetic resonance imaging (MRI) was 97%. Therefore, pazopanib served as a promising, well-tolerated therapy for DT/AF in the AYA population.